Combination therapy before surgery for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative gastric or gastroesophageal junction cancer (Siewert type II or III) that is stage II or III and can be surgically removed.
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your organs (like blood, kidneys, liver) are working well, based on blood tests.
- You are willing to provide blood, stool, and tumor tissue samples for research.
- You do not have active autoimmune disease, uncontrolled infections, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and targeted radiation for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this approach helps shrink tumors or slow the disease.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.